



Amalia Herszkowicz is a Health tech entrepreneur with over 20 years of c-level experience, Amalia serves as the COO at Hadassah Cancer Research Institute (HCRI), leading the translation research achievements done in one of Israel's largest cancer institutes. Prior to HCRI, Amalia was the CEO and Board Member of OBCTCD24 and Cancerend24, clinical-stage companies, developing solutions for the COVID19-related disorder, from concept to Ph-II stage in track record time of 18 months, and a pan cancer screening test for early detection of 11 types of cancer. Prior To OBCT, Amalia was co-founder and COO at Cardiacare, developing detection and treatment for cardiac rhythm disorders. Past positions include VP-BD of Insuline Medical and managerial positions at JCS. Amalia holds an MBA from Manchester University